Bank of New York Mellon’s Aralez Pharmaceuticals Inc. ARLZ Stock Holding History

Bank of New York Mellon’s Portfolio ARLZ Stock Details ARLZ Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	–	Sell	-51,690	Closed	-$19K	–	4331
2018 Q2	$19K	Sell	51,690 -632	-1%	-$518	﹤0.01%	4178
2018 Q1	$79K	Sell	52,322 -8,250	-14%	-$14.4K	﹤0.01%	4101
2017 Q4	$86K	Buy	60,572 +6,162	+11%	+$10.1K	﹤0.01%	4127
2017 Q3	$125K	Buy	54,410 +2,769	+5%	+$3.71K	﹤0.01%	3972
2017 Q2	$71K	Sell	51,641 -756	-1%	-$1.09K	﹤0.01%	4087
2017 Q1	$112K	Sell	52,397 -28,676	-35%	-$108K	﹤0.01%	4005
2016 Q4	$358K	Sell	81,073 -2,004	-2%	-$9.51K	﹤0.01%	3720
2016 Q3	$402K	Buy	83,077 +300	+0.4%	+$1.37K	﹤0.01%	3637
2016 Q2	$274K	Sell	82,777 -112,592	-58%	-$425K	﹤0.01%	3782
2016 Q1	$694K	Buy	+195,369	New	+$1.01M	﹤0.01%	3273

Other funds holding ARLZ

Glenmede Trust Philadelphia, Pennsylvania $22.7B AUM

Bank of New York Mellon's ARLZ Position: Q3 2018 in Review

Bank of New York Mellon sold out of Aralez Pharmaceuticals Inc. (ARLZ) in Q3 2018, closing a stake of 51,690 shares — an estimated $19K sold.

Bank of New York Mellon first reported a position in ARLZ in Q1 2016 and held it in 10 quarters. The position peaked at $694K in Q1 2016. 4 funds tracked by Wall St. Rank hold ARLZ as of Q3 2018.

Bank of New York Mellon reported no remaining Aralez Pharmaceuticals Inc. position as of Q3 2018 after selling out during the quarter.
Bank of New York Mellon sold 51,690 Aralez Pharmaceuticals Inc. shares in Q3 2018, an estimated $19K.
Bank of New York Mellon first reported a position in Aralez Pharmaceuticals Inc. in Q1 2016 and held it in 10 quarters.
Bank of New York Mellon's Aralez Pharmaceuticals Inc. position peaked at $694K in Q1 2016.
4 funds tracked by Wall St. Rank held Aralez Pharmaceuticals Inc. as of Q3 2018.

Based on Bank of New York Mellon's 13F filing for Q3 2018, filed 9 Nov 2018.